4-AcO-MALT

Last updated

4-AcO-MALT
4-AcO-MALT structure.png
Clinical data
Other names4-Acetoxy-MALT; 4-Acetoxy-N-methyl-N-allyltryptamine
Drug class Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C16H20N2O2
Molar mass 272.348 g·mol−1
3D model (JSmol)
  • C=CCN(CCc1c[nH]c2c1c(ccc2)OC(=O)C)C
  • InChI=InChI=1S/C16H20N2O2/c1-4-9-18(3)10-8-13-11-17-14-6-5-7-15(16(13)14)20-12(2)19/h4-7,11,17H,1,8-10H2,2-3H3
  • Key:PGBFYUDKPCYIEB-UHFFFAOYSA-N

4-AcO-MALT, or 4-acetoxy-MALT, also known as 4-acetoxy-N-methyl-N-allyltryptamine, is a psychedelic drug of the tryptamine family. [1] [2] [3] It is the acetate ester of 4-HO-MALT. [1] [2] [3]

Contents

The drug is assumed to act as a prodrug of the serotonergic psychedelic 4-HO-MALT. [1] 4-HO-MALT is a serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT2 receptors. [2] The receptor interactions of 4-AcO-MALT have also been studied. [2] [3]

4-AcO-MALT was first described in the scientific literature by at least 2021. [1] It was encountered as a novel designer drug. [4] [5]

See also

References

  1. 1 2 3 4 Pham DN, Chadeayne AR, Golen JA, Manke DR (1 February 2021). "Psilacetin derivatives: fumarate salts of the methyl–ethyl, methyl–allyl and diallyl variants of the psilocin prodrug". Acta Crystallographica Section E. 77 (Pt 2): 101–106. Bibcode:2021AcCrE..77..101P. doi: 10.1107/S2056989021000116 . ISSN   2056-9890. PMC   7869532 . PMID   33614134.
  2. 1 2 3 4 Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, et al. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacology & Translational Science. 6 (4): 567–577. doi:10.1021/acsptsci.2c00222. PMC   10111620 . PMID   37082754.
  3. 1 2 3 Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (July 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics" (PDF). Neuron. doi:10.1016/j.neuron.2025.06.012. PMID   40683247.
  4. ↑ Miller JJ, Yazdanpanah M, Colantonio DA, Beriault DR, Delaney SR (2024). "New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory". Clinical Biochemistry. 133–134 110810: 110810. doi:10.1016/j.clinbiochem.2024.110810. PMID   39181179.{{cite journal}}: CS1 maint: article number as page number (link)
  5. ↑ Axelsson MA, Lövgren H, Kronstrand R, Green H, Bergström MA (2022). "Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis". Basic & Clinical Pharmacology & Toxicology. 131 (5): 420–434. doi: 10.1111/bcpt.13786 . ISSN   1742-7835. PMID   36028947.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.